Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04696731 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
A Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma, sponsored by Allogene Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 10
- Study locations
NCT04696731: Active Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma, sponsored by Allogene Therapeutics.
NCT04696731 is a Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Allogene Therapeutics. The registered enrollment target is 120 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04696731, a Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Allogene Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC ALLO-316
- BIOLOGICAL ALLO-647
Study Locations (10)
California
- City of Hope - Duarte
- UCLA Medical Center - Los Angeles
- UCSF Medical Center - San Francisco
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Georgetown University Hospital - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Providence Portland Medical Center - Portland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT04696731 still lists
NCT04696731 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher).
The record links to 1 condition, with Advanced/Metastatic Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04696731 lists 10 locations in 8 states (California, Connecticut, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT04696731 about?
NCT04696731 is a clinical study titled "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma". This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclo...
What is the current status of trial NCT04696731?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2021-02-24. Estimated completion is 2025-12.
What conditions does trial NCT04696731 study?
This clinical trial studies the following conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT04696731?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ALLO-316 (GENETIC), ALLO-647 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04696731?
This trial is sponsored by Allogene Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04696731 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04696731's enrollment target sits among peer trials
120 479th of 2000 higher than 1,503 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI